Abstract
Antiviral treatment of hepatitis B virus (HBV) cirrhosis using entecavir or tenofovir suppresses replication of HBV and can reverse liver insufficiency in some cases, which might imply delisting. After liver transplantation, combination HBV prophylaxis with low-dose hepatitis B immune globulin and antivirals effectively prevents HBV recurrence in >90 % of transplant recipients. Some forms of prevention of HBV recurrence should be continued indefinitely post-transplant, but in patients with a low risk of recurrence (i.e., HBV DNA levels undetectable pre-transplant), discontinuation of hepatitis B immune globulin (HBIG) is possible if patients are treated with long-term nucleos(t)ide(s) analogue(s) therapy. A more cautious approach is necessary for patients with high pre-transplant HBV replication, patients with HIV or hepatitis D virus coinfection or preexisting HBV drug resistance, those with a high risk of hepatocellular carcinoma recurrence, and those at risk of noncompliance with antiviral therapy. In this group, HBIG-free prophylaxis cannot be recommended.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
